Godavari Drugs Limited reported a net profit of ₹408.91 lakh for the financial year ended March 31, 2026, with revenue from operations at ₹10580.81 lakh. The company's Board of Directors approved the audited standalone financial results for the quarter and year ended March 31, 2026, at a meeting held on May 27, 2026. The statutory auditors, M/s Ayyadevara & Co., issued an unmodified opinion on the results.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a net profit of ₹129.08 lakh on revenue from operations of ₹3316.31 lakh. Total revenue for the quarter stood at ₹3330.43 lakh. In comparison, the net profit for the previous financial year ended March 31, 2025, was ₹438.00 lakh, with revenue from operations of ₹11335.01 lakh. The company reported a basic earnings per share (EPS) of ₹5.43 for FY26, compared to ₹5.82 in the previous year.

Key Appointments and AGM

Based on the Audit Committee's recommendation, the Board appointed M/s. S.K. Lahoti Associates as Internal Auditors and M/S. Bharathula & Associates as Cost Auditors for the financial year 2026-27. The appointment of the Cost Auditor is subject to ratification by shareholders at the Annual General Meeting. The Board also convened the 38th Annual General Meeting for September 25, 2026, at 03:00 p.m. via Video-Conferencing.

Capital Structure and Fund Utilization

During March 2026, the company made a preferential allotment of 25,96,935 equity shares of ₹10 each at a premium of ₹79 per share. Post-allotment, the total number of shares increased to 1,01,27,435. The company confirmed there were no deviations in the utilization of proceeds from the preferential issue during the quarter and year ended March 31, 2026. Funds raised amounting to ₹4411.73 lakh were utilized towards capital expenditure and working capital requirements.

Compliance and Disclosures

The company confirmed there were no defaults on loans and debt securities during the quarter ended March 31, 2026. The trading window for dealing in the company's securities, which closed on April 1, 2026, will remain shut until 48 hours after the declaration of the financial results. The filing was submitted by Venkatesh Achanta, Company Secretary & Compliance Officer.

Godavari drugs Limited has submitted its mandatory compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the certificate with BSE Limited on April 8, 2026, fulfilling its regulatory obligations under the Securities and Exchange Board of India framework.

SEBI Compliance Certificate Details

The certificate was issued under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018, covering the quarter ended March 31, 2026. CIL Securities Limited, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate on April 7, 2026.

Dematerialization Compliance Confirmation

CIL Securities Limited confirmed that all securities received from depository participants for dematerialization during the quarter were properly processed according to regulatory requirements. The registrar verified that securities comprised in the certificates have been listed on stock exchanges where the company's earlier issued securities are traded.

The compliance process included several key activities:

• Securities received from depository participants were confirmed to depositories
• Security certificates received for dematerialization were mutilated and cancelled after due verification
• Names of depositories were substituted in the Register of Members as registered owners
• All processes were completed within the stipulated timeframe

Regulatory Submission Process

Company Secretary and Compliance Officer Venkatesh Achanta digitally signed and submitted the certificate to BSE Limited. The submission was made with reference to the company's scrip code 530317, ensuring proper identification and record-keeping by the stock exchange.

The certificate submission demonstrates Godavari Drugs Limited's adherence to SEBI's depository regulations, which are designed to ensure transparency and proper handling of securities in dematerialized form. This quarterly compliance requirement helps maintain investor confidence and regulatory oversight in the securities market.